{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-046501","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.481861+00:00","generated_at":"2026-05-30T02:39:25.596053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance","bullets":["Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.","GAAP diluted EPS from continuing ops $0.12; adjusted continuing ops EPS $0.49.","Total Baxter GAAP diluted EPS $0.27; adjusted total diluted EPS $0.80, exceeding prior guidance.","North Cove facility restarted highest-throughput IV solutions line after Hurricane Helene.","Pending sale of Kidney Care business is a key milestone; hurricane expected to impact near-term financials."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-046501","json":"https://secwatch.observer/filing/0001628280-24-046501.json","markdown":"https://secwatch.observer/filing/0001628280-24-046501.md","text":"https://secwatch.observer/filing/0001628280-24-046501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/0001628280-24-046501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828024046501/bax-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:39:25.596053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}